Quilizumab
Based on 1 Customer Validation
Quilizumab (Anti-Human IGHE Recombinant Antibody; 47H4; MEMP1972A) is a monoclonal antibody that targets FcγRIIIa and the M1 prime segment of human membrane-bound IgE. Quilizumab has enhanced FcγRIIIa binding affinity and activity against IgE class-switched B cells, and reduces serum IgE levels by inducing antibody-dependent cell-mediated cytotoxicity and apoptosis through cross-linking of membrane-bound IgE receptors. Quilizumab depletes IgE-producing cells; it also directly binds the membrane-bound M1 prime domain on IgE class-switched cells to inhibit IgE production. Quilizumab is used in research on allergic asthma and allergic diseases (asthma, allergic rhinitis).
For research use only. We do not sell to patients.
- Purity : 99.56%
- CAS No.: 1228538-47-3
- Molecular Weight:146.5 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IGHE
In Vitro
Quilizumab (afucosylated anti-M1 prime antibody) after afucosylation modification shows approximately 24-fold and 7-fold increases in binding affinity for human FcγRIIIa-F158 and FcγRIIIa-V158 receptors, respectively[1].
Quilizumab (0.0051-10000 ng/mL; 3 h) mediates potent ADCC activity against Daudi B cells transfected with membrane-bound IgE, exhibiting approximately 10-fold enhanced ADCC potency compared with the fucosylated wild-type anti-M1 prime antibody[1].
Quilizumab (0.001-25 μg/mL; 72 h) induces apoptosis in Daudi B cells transfected with membrane-bound IgE, with pro-apoptotic potency comparable to that of the fucosylated wild-type anti-M1 prime antibody[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Daudi human B lymphoma cells transfected with human membrane IgE
-
Concentration:0.001, 0.01, 0.1, 1, 10, 25 μg/mL
-
Incubation Time:72 h
-
Result:Induced apoptosis of target cells with no significant differences in maximal percent apoptosis or dose-response compared to the wildtype antibody.
In Vivo
Quilizumab inhibits the production of new allergen-specific IgE induced by allergen stimulation in biological model systems related to allergic asthma[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID-beige mice (sublethally irradiated with 3.5 Gy; reconstituted with human PBMCs)[1]
-
Dosage:3, 30, 300 μg
-
Administration:i.p.; days 0, 4, and 7
-
Result:Reduced human IgE in serum at all doses (3, 30, 300 μg) with maximal activity.
Exhibited approximately 100-fold higher potency than the wildtype counterpart, showing comparable activity at 1/100th the dose.
Did not affect human IgM levels.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IgE Protein, Human (HEK293, His, HY-P73907) can bind Quilizumab. The EC50 for this effect is 486.8 ng/mL.
Chemical Information
-
CAS No. 1228538-47-3
-
Appearance Liquid
-
Molecular Weight 146.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Quilizumab]
-
Synonyms
Anti-Human IGHE Recombinant Antibody; 47H4; MEMP1972A
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Quilizumab Related Classifications
HY-P99313 Related Classifications
Powered by Bioz
Keywords
- Quilizumab
- 1228538-47-3
- Anti-Human IGHE Recombinant Antibody
- 47H4
- MEMP1972A
- Drug Derivative
- Fc Receptor (FcR)
- Apoptosis
- Daudi B cells
- FcγRIIIa
- allergic asthma
- allergic rhinitis
- IgE-switched B cells
- human membrane IgE
- apoptosis
- human PBMC-SCID mouse model
- M1 prime segment
- antibody-dependent cell-mediated cytotoxicity
- Inhibitor
- inhibitor
- inhibit